- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03001453
Intraoperative Liposomal Bupivacaine vs. Bupivacaine for Total Hip Replacement Pain Management
Post-surgical Pain Care Pathways During Enhanced Recovery Surgery Using Exparel (Bupivacaine Liposome Injectable Suspension) Plus Bupivacaine With Epinephrine Versus Bupivacaine.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
All surgeries were performed by the same orthopaedic surgeon. Two groups, one receiving Exparel® (bupivacaine liposome injectable suspension) plus bupivacaine with epinephrine (LB group) and the other receiving bupivacaine with epinephrine (Control group), will be compared using post-operative pain scores, hospital length of stay, time to ambulation, falls, narcotic use, and narcotic-related adverse effects. Aside from hospital length of stay, all outcomes were recorded for up to 72 hours following surgery. An a priori power analysis was performed to calculate the total number of patients that needed to be enrolled to achieve a minimum 90% power, with the threshold of statistical significance set to 0.05. Based on a previous study reporting a mean oral opioid consumption of 57.04mg ± 25.6 at 24 hours post THR, a mean difference of 17.14mg was considered to be clinically significant. Thus, at least 26 patients were necessary in each group for an adequately powered assessment. The diagnosis for osteoarthritis was determined by patient history, physical examination, and imaging findings. Each patient received a thorough explanation of the protocol, and willing patients signed an informed consent form. All patients underwent a personal preoperative education program regarding pre, intra-, and post-procedural information including physical therapy, expectations, discharge goals, home therapy, and pain management. After written consent was collected, the form was sent to the hospital pharmacy for randomization. Envelopes were randomized, sealed, numbered, and given to the pharmacy staff, ultimately dispensing the envelopes to the nurse in the operating room in numerical order. The pharmacy documented the required information, selected medication, and drug accountability forms according to the contents of the envelopes.
A nurse delivered study drugs to the operating room in a sealed, non-descriptive envelope. During the standard anterior approach procedure, an anesthesiologist administered fentanyl or hydromorphone as needed for analgesia. The local anesthetics were administered after reduction of the implants. Patients in the LB group received 20cc liposomal bupivacaine, 40cc 0.25% bupivacaine with epinephrine, and 20cc of normal saline. Each patient in the control group received 60cc of 0.25% bupivacaine with epinephrine. Using a 20-gauge spinal needle, the local anesthetics were injected using a deep tissue administration technique. Structures innervated by the femoral nerve, superior gluteal nerve, or lateral femoral cutaneous nerve were considered suitable for injection. Throughout administration, frequent aspirations were performed to check for blood and minimize the risk of intravascular injection. The patients, surgical team, and floor staff was blinded to the local anesthetic drugs given.
During hospitalization, patients were observed, evaluated and treated according to postoperative protocols. Patients received opioids for pain management as needed, which was routinely documented by hospital staff. Opioids included fentanyl, hydromorphone, oxycodone, codeine, tramadol, morphine, and hydrocodone. All opioid dosages were converted into morphine equivalent dosages for analysis. Each patient began physical therapy within the first 24 hours postoperatively. Patients were discharged when they were able to begin self-care, their pain was controlled utilizing an oral regimen, and they were able to tolerate oral medication intake.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Illinois
-
Hinsdale, Illinois, Estados Unidos, 60521
- Adventist Hinsdale Hospital
-
Westmont, Illinois, Estados Unidos, 60559
- American Hip Institute
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patients scheduled to undergo primary unilateral total hip replacement
- Patients diagnosed with hip osteoarthritis
- Patients failed to improve with conservative measures
- Patients willing and able to sign informed consent
Exclusion Criteria:
- Revision total hip replacement
- Bilateral total hip replacement
- Birmingham hip resurfacing
- Patients with hepatic/kidney disease
- Patients with a known allergy to bupivacaine or other local anesthetics
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Comparador activo: Liposomal bupivacaine
Periarticular infiltration cocktail of 20cc of liposomal bupivacaine with 20cc of normal saline and 40cc of 0.25% bupivacaine with epinephrine
|
266mg liposomal bupivacaine
Otros nombres:
0.25% bupivacaine with epinephrine
Otros nombres:
Normal saline
Otros nombres:
|
Comparador activo: Bupivacaine with epinephrine
Periarticular infiltration cocktail of 60cc of 0.25% bupivacaine with epinephrine
|
0.25% bupivacaine with epinephrine
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Patient Morphine Equivalent Consumption
Periodo de tiempo: 72 hours postoperation, divided into six 12-hour periods
|
All opioid doses were administered to the patient at 12-hour intervals post-surgery.
Doses were recorded till either of the following criteria was met, the patient was discharged or the 72-hour post-surgery timeframe ended.
The doses were then collected and converted to OMEs, in milligrams.
|
72 hours postoperation, divided into six 12-hour periods
|
Change in Patient-reported Visual Analog Scale (VAS) Pain Intensity Score
Periodo de tiempo: 72 hours post-operation, divided into six 12-hour periods
|
Patient-reported VAS pain intensity score (0 = no pain, 10 = worst pain possible) will be collected.
Mean VAS scores for the 72-hour period were calculated using the cohort's reported average pain scores at each 12-hour interval.
|
72 hours post-operation, divided into six 12-hour periods
|
Time to Ambulation More Than 20 Feet (in Hours)
Periodo de tiempo: from time of surgery until patient first ambulates more than 20 feet or 72 hours post-surgery or patient discharge, whichever comes first
|
The length of time (in hours) until the patient first ambulates more than 20 feet from the time of surgery will be recorded.
|
from time of surgery until patient first ambulates more than 20 feet or 72 hours post-surgery or patient discharge, whichever comes first
|
Length of Stay (LOS, in Days)
Periodo de tiempo: From time of surgery until patient is discharged, an average of 1.5 days.
|
From time of surgery until patient is discharged, an average of 1.5 days.
|
|
Number of Patients That Experienced a Fall
Periodo de tiempo: 72 hours postoperation
|
72 hours postoperation
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Benjamin G Domb, MD, American Hip Institute
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Complicaciones Postoperatorias
- Dolor
- Manifestaciones neurológicas
- Dolor Postoperatorio
- Efectos fisiológicos de las drogas
- Agentes adrenérgicos
- Agentes neurotransmisores
- Mecanismos moleculares de acción farmacológica
- Depresores del sistema nervioso central
- Agentes Autonómicos
- Agentes del sistema nervioso periférico
- Agentes del sistema sensorial
- Anestésicos
- Agonistas alfa adrenérgicos
- Agonistas adrenérgicos
- Anestésicos Locales
- Agentes broncodilatadores
- Agentes antiasmáticos
- Agentes del sistema respiratorio
- Agonistas beta adrenérgicos
- Simpaticomiméticos
- Agentes vasoconstrictores
- Midriáticos
- Bupivacaína
- Epinefrina
Otros números de identificación del estudio
- AHI-001
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Liposomal Bupivacaine
-
National Cancer Institute (NCI)TerminadoQueratosis actínica | Carcinoma de células escamosas de la piel | Cáncer de piel recurrente | Carcinoma de células basales de la pielEstados Unidos
-
Applied GeneticsDesconocidoCondición precancerosaEstados Unidos, Alemania, Reino Unido
-
InnoMedica Schweiz AGActivo, no reclutandoEnfermedad de ParkinsonSuiza
-
HanAll BioPharma Co., Ltd.TerminadoDermatitis atópica leve a moderadaEstados Unidos
-
Milton S. Hershey Medical CenterTerminado
-
Jazz PharmaceuticalsAdvice Pharma S.r.l.ReclutamientoLeucemia mieloide aguda (LMA) | Leucemia mieloide aguda relacionada con la terapia | Leucemia mieloide aguda con cambios relacionados con mielodisplasiaItalia
-
Tehran University of Medical SciencesMashhad University of Medical Sciences; Center for Research and Training in Skin...TerminadoLeishmaniasis cutáneaIrán (República Islámica de
-
Emory UniversityYour Energy Systems, LLCRetirado
-
Banaras Hindu UniversityRajendra Memorial Research Institute of Medical SciencesDesconocido
-
Holger JoswigTerminadoHernia de disco lumbar | Hernia de disco cervicalSuiza